[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"National Institute on Deafness and Other Communication Disorders (NIDCD)\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":175},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,45,70,101,124,147],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":4,"leadSponsor":41,"locationsCount":44},"100180885","normal-values-in-hearing-and-balance-testing-100180885",false,"NCT01629108","Normal Values in Hearing and Balance Testing","Normative Values in Audiovestibular Testing","* INCLUSION CRITERIA:\n\nHealthy adult volunteers:\n\n* Healthy adults, aged 18-80 years\n* Able to provide informed consent\n* Normal hearing sensitivity, defined as pure-tone thresholds less than or equal to 25 dB HL, or when the pure-tone threshold exceeds 25 dB HL, it must be less than or equal to the median threshold for the appropriate gender- and age-based group, for 250-8000 Hz (Morrell et al, 1996, ISO-7029, 2000).\n* No air-bone gaps in excess of 10 dB for 500-4000 Hz.\n* Normal middle ear function as indicated by normal 226 Hz tympanograms bilaterally, defined as middle ear pressure between more or less 100 decaPascals, and peak compensated static compliance between 0.3-1.5 milliliters\n* American English as a first language for those participating in study tasks evaluating auditory processing.\n* Able to refrain from caffeine and alcohol for 48 hours before vestibular study sessions because both agents may modify the test results.\n\nEXCLUSION CRITERIA:\n\n* History of auditory and\u002For vestibular disorders (e.g., Meniere s syndrome, labyrinthitis).\n* Evidence of active outer or middle ear disease or anomaly (e.g. otitis media, stenotic ear canal, otorrhea)\n* History of chronic (fluid in middle ear for more than 4 months) or recurrent otitis media (more than 4 episodes of acute otitis media in one year)\n* History of ear surgery other than PE tubes\n* Current PE tubes\n* History of treatment with ototoxic medications (e.g. cisplatin, aminoglycoside antibiotics)\n* Unable to discontinue medications that can interfere with vestibular test results for the 48 hours immediately preceding a vestibular study session. These include any and all anti-dizziness medications (such as Antivert), prescription pain medications (such as Percocet), prescription headache medications (such as Imitrex), sleeping pills (such as Ambien), anti-seizure medications (such as Topamax), and\u002For antihistamines (such as Benadryl).\n* Current diagnosis from the Diagnostic and Statistical Manual of Mental Disorders (DSM IV) of a psychiatric disorder or on medications for a psychiatric disorder in the past two years, including any or all antidepressants, anxiolytics, or psychostimulant drugs.\n* Cognitive impairment as evidenced by a score \\\u003C26 on the Montreal Cognitive Assessment (MoCA).\n* Attention deficit hyperactivity disorder (ADHD) as evidenced by a score of greater than or equal than or equal to 4 on the Adult ADHD Self Report Scale (Kessler et al., 2005).\n* History or diagnosis of a central nervous system disorder, including but not limited to:\n\n  * Intracranial tumors\n  * Cerebrovascular disease\n  * Degenerative CNS disorder\n  * CNS trauma\n  * Encephalitis\n  * Meningitis\n* Current diagnosis of speech and\u002For language disorders, autism, auditory neuropathy, or auditory processing disorder; or in therapy for these disorders in past 2 years.\n* Reduced visual acuity preventing ability to see the visual targets used for vestibular and balance testing as evidenced by corrected visual acuity worse than 20\u002F25 on a Snellen chart for those participating in vestibular tasks.\n* Ocular motor impairment preventing ability accurately follow the visual target used for calibration and\u002For ocular motor tasks for those participating in the vestibular tasks.\n* Employees and staff of the Audiology Unit, Otolaryngology Branch, NIDCD.\n* Reduced balance or postural instability as evidenced by a Timed Up and Go score greater than or equal to 11.1 seconds (Whitney et al., 2004) for adults \\\u003C65 years of age and \\>12.6 seconds for adults 65-80 years of age (Shumway-Cook et al.,2000) and\u002For Activities-specific Balance Confidence Score \\\u003C67% for those participating in vestibular study tasks.\n\nHealthy children volunteers:\n\nINCLUSION CRITERIA:\n\n* Healthy children, aged 5 years-0 months to 17 years-11 months\n* Normal hearing sensitivity, defined as pure-tone thresholds of 15 dB HL or better for 250-8000 Hz\n* Normal middle ear function as indicated by normal 226 Hz tympanograms bilaterally, defined as middle ear pressure between more or less 100 decaPascals, and peak compensated static compliance between 0.2-1.5 milliliters\n* American English as a first language for those participating in study tasks evaluating auditory processing.\n* Ability to follow the verbal instructions and commands for study tests\n* Able to refrain from alcohol and caffeine intake for 48 hours before vestibular study sessions because caffeine may modify the test results\n* Weight greater than 40 pounds for those participating in vestibular tasks that include CDDP\n\nEXCLUSION CRITERIA:\n\n* History of auditory and\u002For vestibular disorders (e.g. Meniere syndrome, enlarged vestibular aqueduct).\n* Evidence of active outer or middle ear disease or anomaly (e.g. otitis media, stenotic ear canal, otorrhea)\n* History of chronic (fluid in middle ear for more than 4 months) or recurrent otitis media (more than 4 episodes of acute otitis media in one year)\n* History of ear surgery other than PE tubes\n* Current PE tubes\n* History of treatment with ototoxic medications (e.g. cisplatin, aminoglycoside antibiotics)\n* Unable to discontinue medications that can interfere with vestibular test results for the 48 hours immediately preceding a vestibular study session. These include any and all anti-dizziness medications (such as Antivert), prescription pain medications (such as Percocet), prescription headache medications (such as Imitrex), sleeping pills (such as Ambien), anti-seizure medications (such as Topamax), and\u002For antihistamines (such as Benadryl).\n* Current diagnosis from the Diagnostic and Statistical Manual of Mental Disorders (DSM IV) of a psychiatric disorder or on medications for psychiatric disorder in the past two years, including any or all antidepressants, anxiolytics, or psychostimulant drugs.\n* Cognitive impairment as evidenced by a standard score less than 85 on the Peabody Picture Vocabulary Test (Fourth Edition)\n* Attention deficit hyperactivity disorder (ADHD) as evidenced by a score of greater than or equal to 6 on the SNAP IV\n* History or previous diagnosis of a central nervous system disorder, including but not limited to:\n\n  * Intracranial tumors\n  * Cerebrovascular disease\n  * Degenerative CNS disorder\n  * CNS trauma\n  * Encephalitis\n  * Meningitis\n* Current diagnosis of speech and\u002For language disorders or delays, autism, auditory neuropathy, or auditory processing disorder; or in therapy of these disorders in past 2 years.\n* Reduced visual acuity preventing ability to see the visual targets used for vestibular and balance testing as evidenced by corrected visual acuity worse than 20\u002F25 on a Snellen chart for those participating in vestibular study tasks.\n* Ocular motor impairment preventing ability to see or accurately follow the visual target used for ocular motor tasks for those participating in the vestibular study tasks.\n* Reduced balance or postural instability as evidenced by a Timed Up and Go score of greater than or equal to 9.4 seconds for those participating in vestibular study tasks.",true,"ALL","5 Years","80 Years",{"count":21,"type":22},500,"ESTIMATED","OBSERVATIONAL","Background:\n\n\\- Researchers at the National Institutes of Health give many tests of hearing and balance. These tests can help detect problems that affect hearing or balance. It is important to know exactly how healthy people perform on each of these tests. This information will indicate when a test result is normal and when a test result shows a problem. Researchers also want to determine the best methods for each test.\n\nObjectives:\n\n\\- To test different types of hearing and balance tests, and collect information on normal values for each test.\n\nEligibility:\n\n\\- Healthy volunteers between 5 and 80 years of age.\n\nDesign:\n\n* This study will require a single visit to the National Institutes of Health Clinical Center. It will include both screening tests and study tests of hearing and balance. Sometimes, a second visit may be required if a test is designed to measure the same thing on 2 different days. Each visit will last between 2 and 5 hours, depending on the number of tests scheduled per visit.\n* Participants will have a physical exam and medical history. They will also have basic tests to check for normal hearing and balance.\n* Participants may have different hearing tests, including the following:\n* Auditory Evoked Potentials to study how the ears and brain handle sound information.\n* Auditory Processing Tests to study how a person processes complex sounds like speech in background noise.\n* Tests of middle ear and inner ear function.\n* Participants may have different balance and inner ear tests, including the following:\n* Balance test on a tilting platform.\n* Different tests to measure how well the eyes, ears, and brain work together to help maintain balance.\n* Treatment will not be needed as part of this study.",[26],"Healthy Volunteer",[28,29,30,31,32,33],"Normative Data","Vestibular","Auditory","Healthy Volunteers","Hearing","Natural History","RECRUITING","2026-06-27",{"date":37,"type":38},"2026-06-30","ACTUAL",{"date":40,"type":38},"2012-09-21",{"name":42,"class":43},"National Institute on Deafness and Other Communication Disorders (NIDCD)","NIH",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":16,"sex":17,"minAge":51,"maxAge":19,"enrollmentInfo":52,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":54,"conditions":55,"keywords":59,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":44},"100424391","deep-phenotyping-of-hearing-instability-disorders-cohort-establishment-biomarker-identification-development-of-novel-phenotyping-measures-and-discovery-of-therapeutic-targets-100424391","NCT04806282","Deep Phenotyping of Hearing Instability Disorders: Cohort Establishment, Biomarker Identification, Development of Novel Phenotyping Measures, and Discovery of Therapeutic Targets","* NCLUSION CRITERIA:\n\nAffected Adults\n\nIn order to be eligible to participate in this study as a subject with HI, an individual must meet all of the following criteria:\n\n1. Provision of signed and dated informed consent.\n2. Stated willingness to comply with all study procedures and availability for the duration of the study\n3. All genders, aged 18-80 years\n\n   Diagnosed with hearing instability, defined as documented hearing instability on serial audiometry with sensorineural hearing loss (SNHL) greater than 30 dB HL at one or more frequencies on at least one hearing test. Inclusion will require documentation of clinically significant change in hearing (either worsening or improvement) between at least 2 hearing tests or documentation of a sudden change in hearing. Clinically significant change in hearing will be defined by a change of10 dB at any three frequencies, 15 dB at any two frequencies, or at least 20 dB at one frequency. A sudden change in hearing will be defined as at least a 30 dB difference at 3 consecutive frequencies in the affected ear as compared to the contralateral ear.\n4. No air-bone gaps in excess of 10 dB for 500-4000 Hz indicative of conductive HL in at least 1 ear.\n5. For females of reproductive potential: Negative pregnancy test at start of study\n\nUnaffected Adults\n\nIn order to be eligible to participate in this study as a healthy volunteer, an individual must meet all of the following criteria:\n\n1. Provision of signed and dated informed consent.\n2. Stated willingness to comply with all study procedures and availability for the duration of the study\n3. All genders, aged 18-80 years\n4. No air-bone gaps in excess of 10 dB for 500-4000Hz indicative of conductive HL in at least one ear.\n5. Normal middle ear function as indicated by normal 226 Hz tympanograms bilaterally, defined as middle ear pressure between plus minus 100 decaPascals, and peak compensated static compliance between 0.3-1.8 milliliters\n6. For females of reproductive potential: Negative pregnancy test at start of study\n\nEXCLUSION CRITERIA:\n\nAffected and unaffected individuals who meet any of the following criteria will be excluded from participation in this study:\n\n1. Presence of non-MRI compatible devices (cardiac pacemaker, meta\\\u003Cspecific devices (e.g., cardiac pacemaker)\n2. Pregnancy or lactation\n3. Known allergic reactions to gadolinium\n4. Febrile illness within 2 weeks that could affect immune profiling\\*\n5. Evidence of active outer or middle ear disease or anomaly (e.g. otitis media, stenotic ear canal, otorrhea)\n6. History of chronic, as defined by fluid in the middle ear for more than 4 months, or recurrent otitis media, as defined by more than 4 episodes of acute otitis media in one year.\n7. Current PE tubes\n8. Bilateral profound (Pure tone average (PTA) \\> 90 dB HL) sensorineural hearing loss\n9. History or diagnosis of a central nervous system disorder, including but not limited to:\n\n   1. Intracranial tumors\n   2. Cerebrovascular disease\n   3. Degenerative CNS disorder\n   4. CNS trauma\n   5. Encephalitis\n   6. Meningitis\n10. Unable to discontinue medications that can interfere with vestibular test results for the 48 hours immediately preceding a vestibular study session. These include any and all anti-dizziness medications (such as Antivert), alcohol, caffeine, prescription pain medications (such as Percocet), prescription headache medications (such as Imitrex), sleeping pills (such as Ambien), anti-seizure medications (such as Topamax), and\u002For antihistamines (such as Benadryl).\n11. Current diagnosis from the Diagnostic and Statistical Manual of Mental Disorders (DSM IV) of schizophrenia, bipolar disorder, or psychosis.\n12. Unstable intercurrent illness that in the judgment of the PI could prevent or confound collection of data.\n\nProspective study subjects who are cognitively impaired and lack consent capacity, will not be enrolled.\n\n\\*Participants suspected of having COVID-19 will be moved to the designated COVID-19 unit and tested for SARS CoV-2 and Respiratory Pathogen Panel per guidance from NIH CC Clinical Practice Safety Guidelines. Possible COVID-19 infections identified by phone screen will not be eligible for study protocol until infection resolved.","18 Years",{"count":53,"type":22},210,"Background:\n\nDisorders of hearing instability (HI) are poorly characterized and ineffectively treated. HI can cause fluctuations in hearing thresholds and speech understanding. Researchers want to use a specialized form of magnetic resonance imaging (MRI) and blood tests to learn more about HI.\n\nObjective:\n\nTo characterize a cohort of people with HI and to correlate HI with other data, including hearing evaluations, as well as radiologic and immunologic biomarkers of inflammation over time.\n\nEligibility:\n\nAdults ages 18-80 who have symptoms consistent with possible HI.\n\nDesign:\n\nParticipants will be screened with a medical and hearing history and medical record review.\n\nParticipants will have physical exams. Their head and neck will be examined. They will have blood drawn.\n\nParticipants will have hearing tests. They will wear headphones or foam earplugs. They will listen to different tones. They may describe what they hear.\n\nParticipants will have balance tests. They will wear goggles as they watch moving lights or while cold or warm air is blown into their ears. They will sit in a spinning chair in a quiet, dark booth. From a reclining position, they will raise their head while clicking sounds are played into their ears.\n\nParticipants will have MRIs of the inner ear and brain. The MRI scanner is a metal cylinder surrounded by a strong magnetic field. During the MRIs, participants will lie on a table that slides in and out of the scanner. Soft padding or a coil will be placed around their head. They will get a contrast agent through an intravenous catheter.\n\nParticipation will last up to 15 months.\n\n...",[56,57,58],"Meniere's Disease","Enlarged Vestibular Aqueduct Syndrome","Autoimmune Inner Ear Disease",[60,61,30],"Biomarkers","immunoprofiling","2026-06-26",{"date":64,"type":38},"2026-06-29",{"date":66,"type":38},"2021-08-17",{"date":68,"type":22},"2030-12-31",{"name":42,"class":43},{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":4,"eligibilityCriteria":76,"healthyVolunteers":11,"sex":17,"minAge":51,"maxAge":77,"enrollmentInfo":78,"targetDuration":4,"studyType":80,"phases":81,"briefSummary":83,"conditions":84,"keywords":87,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":100},"100432751","phase-2-atorvastatin-to-reduce-cisplatin-induced-hearing-loss-among-individuals-with-head-and-neck-cancer-100432751","NCT04915183","Atorvastatin to Reduce Cisplatin-Induced Hearing Loss Among Individuals With Head and Neck Cancer","Phase II Interventional Study Using Atorvastatin to Reduce Cisplatin-Induced Hearing Loss Among Individuals With Head and Neck Cancer","* INCLUSION CRITERIA:\n\nIn order to be eligible to participate in this study, an individual must meet all of the following criteria evaluated by the study team, including an on-site oncologist:\n\n* Willingness and ability to comply with and participate in all study procedures and availability for the duration of the study\n* Ability to provide consent and provision of signed and dated informed consent form\n* Adult subjects, aged \\>=18\n* Diagnosed with squamous cell carcinoma of the head and neck, confirmed by a pathologic review of surgical or biopsy specimen(s), who meet standard clinical and laboratory criteria and will undergo treatment with concomitant cisplatin-based chemotherapy and radiation with curative intent or treatment with neoadjuvant chemotherapy (NAC). This includes subjects who will be treated with either intensity-modulated radiation therapy (IMRT) or proton radiotherapy, with planned dose to the cochlea \\\u003C35 Gy (to limit confounding effects of radiation64-67). Patients receiving immunotherapy in addition to cisplatin chemoradiation are eligible. Subjects treated with either high-dose cisplatin (typically 100 mg\u002Fm\\^2 x 2-3 doses every three weeks) or low-dose, weekly cisplatin (typically 40 mg\u002Fm\\^2 x 6-7 doses weekly) may enroll. Cisplatin in the neo-adjuvant setting may be given within a combination chemotherapy regimen (e.g TPF= Docetaxel, Cisplatin and 5FU or DC = Docetaxel Cisplatin)\n* Subjects must have hearing thresholds at or better than 70 dB HL at 1, 2, and 4 kHz in at least one ear at the time of their baseline audiogram. CTCAE criteria (primary endpoint) and ASHA criteria (secondary endpoint) are based on changes in hearing in at\n\nleast one ear with one ototoxicity event\u002Fgrade assigned per person.\n\n* Baseline laboratory tests with lab values \\\u003C1.5x the upper limit of normal: aspartate aminotransferase (AST or SGOT); alanine aminotransferase; creatine phosphokinase, creatinine\n* Ability to take oral medication by mouth or by feeding tube and willingness to adhere to the daily atorvastatin or placebo regimen\n* For females of reproductive potential: use of highly effective contraception for at least 1 month prior to enrollment and agreement to use such a method during study participation and for an additional 8 weeks after the end of atorvastatin administration\n\nEXCLUSION CRITERIA:\n\nAn individual who meets any of the following criteria will be excluded from participation in this study:\n\n* Subjects currently taking a statin drug\n* Subjects with bilateral flat, Type B tympanogram\n* Subjects with bilateral cochlear implants\n* Pre-existing liver or kidney disease that in the opinion of the investigator would interfere with taking Atorvastatin 40 mg daily.\n* Subjects with a history of prior treatment with cisplatin chemotherapy\n* Staff members of the NIDCD Sections and of the lead site investigators headed by the PIs\n* Children will be excluded because HNSCC in children under age 18 is exceedingly rare\n* Current use of cimetidine, spironolactone, ketoconazole, cyclosporine, protease inhibitors, gemfibrozil, clarithromycin or itraconazole\n* Pregnancy, lactation, or plan to become pregnant\n* Known allergic reactions to components of atorvastatin or the placebo\n* Other severe or unstable medical conditions which clinical site PI believes increase risk to safety or ability to complete study\n* Expected concomitant use of aminoglycoside antibiotics","100 Years",{"count":79,"type":22},224,"INTERVENTIONAL",[82],"PHASE2","Background:\n\nCisplatin is used to treat head and neck cancer. People who take this drug are at risk for hearing loss. Atorvastatin is a drug used to treat high cholesterol. It might reduce the risk of cisplatin-induced hearing loss.\n\nObjective:\n\nTo find out if atorvastatin reduces hearing loss in people treated with cisplatin and radiation.\n\nEligibility:\n\nPeople ages 18 and older with squamous cell carcinoma of the head and neck who will undergo treatment with cisplatin-based chemotherapy and radiation\n\nDesign:\n\nParticipants will be screened with their medical records.\n\nParticipants currently taking a cholesterol-lowering statin medication are invited to participate in the observational arm of the study. Those not taking such a medication are invited to participate in the interventional arm of the study.\n\nAll participants will have 3 study visits for the purpose of evaluating hearing. One before starting cisplatin treatment, one within 3 months of completing cancer treatment, and one within 2 years of completing cancer treatment. They will have tympanograms. A small flexible tip will be placed in the ear canal. A puff of air will be delivered to assess mobility of the ear drum. They will have hearing tests. They will wear headphones. They will listen to tones that vary in loudness. They will be asked to indicate when they hear a sound. They will complete 3 questionnaires at the time of each hearing test.\n\nParticipants will have 2 visits for blood tests. These will occur upon consent and 12 weeks after. They will be randomly assigned to take the study drug or placebo orally, once daily. They will take it during cisplatin treatment and for 3 months after treatment.\n\nLong-term follow up will include a chart review 2 years after participants complete their cisplatin therapy.",[85,86],"Hearing Loss","Head and Neck Cancer",[88,89,90,91],"Audiogram","Statin","Chemotherapy","Squamous Cell Carcinoma","2026-06-04",{"date":94,"type":38},"2026-06-05",{"date":96,"type":38},"2024-07-10",{"date":98,"type":22},"2030-08-31",{"name":42,"class":43},5,{"id":102,"slug":103,"hasResults":11,"nctId":104,"briefTitle":105,"officialTitle":105,"acronym":4,"eligibilityCriteria":106,"healthyVolunteers":16,"sex":17,"minAge":107,"maxAge":108,"enrollmentInfo":109,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":111,"conditions":112,"keywords":113,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":116,"lastUpdatePostDateStruct":117,"startDateStruct":119,"completionDateStruct":121,"leadSponsor":123,"locationsCount":44},"100400964","natural-history-of-autosomal-dominant-hearing-loss-100400964","NCT04501081","Natural History of Autosomal Dominant Hearing Loss","* INCLUSION CRITERIA:\n* Affected persons with autosomal dominant hereditary sensorineural hearing loss, preferably confirmed by prior genetic testing\n* Affected family members of enrolled participants with known autosomal dominant hereditary hearing loss\n* Unaffected Family Members (Healthy Volunteers) of enrolled participant\n* Adults must be able to provide informed consent\n* Minors must have a parent or guardian able to provide informed consent\n* Subjects must be 3-99 years of age\n\nEXCLUSION CRITERIA:\n\n* Persons with sensorineural hearing loss (SNHL) and\u002For peripheral vestibular dysfunction associated with a non-genetic etiology such as infection, metabolic or immunologic disorders, or exposure to ototoxic agents such as cisplatin, or aminoglycoside antibiotics will not be included in this protocol.\n* Persons with sensorineural hearing loss known to be associated with surgical intervention (e.g. acoustic neuroma removal, failed stapedectomy).\n\nProspective study subjects who are cognitively impaired and lack consent capacity, will not be enrolled. The pre-screening eligibility checklist, which will be used and documented for registration under this protocol, is provided in a separate document.","3 Years","99 Years",{"count":110,"type":22},1100,"Background:\n\nHereditary hearing loss is one of the most common sensory disabilities affecting newborns. The main options for people with hereditary hearing loss are hearing aids and cochlear implants. Both options have their limitations and do not restore biological hearing. Researchers want to learn if gene editing might be a treatment option.\n\nObjective:\n\nTo understand the genes that cause non-syndromic autosomal dominant hearing loss (DFNA) in people with DFNA as well as their family members.\n\nEligibility:\n\nPeople age 3 99 who have DFNA, affected family members of enrolled participants with DFNA, and unaffected family members of enrolled participants\n\nDesign:\n\nParticipants will be screened with a medical and hearing history. Their medical records will be reviewed.\n\nParticipants will have hearing tests. They will wear headphones or earplugs. They will listen to tones, sounds, and words and may be asked to describe what they hear.\n\nParticipants will have balance tests. For these, they will wear googles as they watch moving lights or as cold or warm air is blown into their ears. They will sit in a spinning chair in a quiet, dark booth. From a reclined position, they will raise their head while listening to clicking sounds.\n\nParticipants will have blood drawn through a needle in the arm. Some blood will be used for gene testing.\n\nSome participants will have 2 skin biopsies. The skin will be washed, and a numbing medicine will be injected. Two small pieces of skin will be removed.\n\nParticipants may have a physical exam.\n\nParticipation will last for up to 20 years. Participants may give medical updates once a year.",[85],[114,115,33],"DFNA","Genome Editing","2026-05-06",{"date":118,"type":38},"2026-05-07",{"date":120,"type":38},"2021-02-09",{"date":122,"type":22},"2029-08-21",{"name":42,"class":43},{"id":125,"slug":126,"hasResults":11,"nctId":127,"briefTitle":128,"officialTitle":128,"acronym":4,"eligibilityCriteria":129,"healthyVolunteers":11,"sex":17,"minAge":130,"maxAge":108,"enrollmentInfo":131,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":133,"conditions":134,"keywords":136,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":139,"lastUpdatePostDateStruct":140,"startDateStruct":142,"completionDateStruct":144,"leadSponsor":146,"locationsCount":44},"100490774","collection-of-clinical-data-and-specimens-for-research-in-hearing-balance-taste-smell-voice-speech-and-language-disorders-100490774","NCT05670496","Collection of Clinical Data and Specimens for Research in Hearing, Balance, Taste, Smell, Voice, Speech, and Language Disorders.","* INCLUSION CRITERIA:\n\nIn order to be eligible to participate in this study, an individual must meet all of the following criteria:\n\n* Patients must be age 2 years or older if procedures or treatment are required.\n* Patients at risk, suspected of having, have a history of, or currently have a diagnosed hearing, balance, taste, smell, voice, speech, language, and other ENT disorder.\n* An NIDCD clinical investigator and PI determines it is in the interest of the patient\u002Findividual and NIDCD CRP for the subject to undergo consult, treatment or follow-up at the NIDCD\u002FNIH\n* Patient or their Legally Authorized Representative is able to provide informed consent. The consent form will be signed by parents or guardians of patients under the age of 18.\n* A subset of enrolled participants with known or suspected PIEZO2-related sensory dysfunction may be asked to participate in the remote taste and oral somatosensory testing procedures. Participation in this component is optional and not required for enrollment or continued participation in the parent protocol.\n\nEXCLUSION CRITERIA:\n\nAn individual who meets any of the following criteria will be excluded from participation in this study:\n\n* Candidates who do not meet the inclusion criteria.\n* Candidates who in the opinion of the PI and clinical team have medical or unstable conditions for which NIDCD and CC consultative services are unable to provide or support optimal care\n\nParticipants without known or suspected PIEZO2-related sensory dysfunction will not be asked to complete the sensory testing component. Additional exclusion criteria for taste testing only procedures include:\n\n* Active oral sores, open cuts, or significant oral pain\n* Recent oral surgery or dental procedures within the past 7 days\n* Known allergy or hypersensitivity to tannins or polyphenols\n* Acute upper respiratory infection or conditions that may interfere with taste perception","2 Years",{"count":132,"type":22},600,"Background:\n\nPeople with hearing, balance, and taste, smell, voice, speech, language, and other Ear, Nose, and Throat (ENT) disorders may seek treatment at the National Institute on Deafness and Other Communication Disorders (NIDCD). Some of these people may benefit from enrolling in the NIDCD intramural research program to receive their care. Enrolling will also allow investigators to collect participants clinical data and specimens for future research.\n\nObjective:\n\nThis natural history study has 2 goals: (1) to collect data and specimens that may be used for research; and (2) to evaluate participants who may be candidates for other research studies.\n\nEligibility:\n\nPeople aged 2 years or older with a hearing, balance, and communication disorder. Those at risk or who are suspected of having such a disorder are also eligible.\n\nDesign:\n\nParticipants will be screened. Their medical records will be reviewed.\n\nParticipants will agree to have their medical data used for research. Specimens such as blood or other tissue samples may also be used for research. All data and specimens will be collected during their routine care visits.\n\nAll tests done will be the normal care for each participant s condition. No tests will be done solely for research.\n\nSome of these tests may require blood or tissue samples. Some may use special tools to test hearing and balance. Some may test heart or lung function. These tests may also include different types of imaging scans.\n\nAll tests will be explained. Participants may ask questions at any time.\n\nParticipants may remain in this study for up to 2 years. If they need further care, they may sign a new consent.\n\n...",[85,135],"Deafness",[135,32,137,29,138,33],"Speech","Audiology","2026-04-25",{"date":141,"type":38},"2026-04-28",{"date":143,"type":38},"2023-03-08",{"date":145,"type":22},"2032-12-01",{"name":42,"class":43},{"id":148,"slug":149,"hasResults":11,"nctId":150,"briefTitle":151,"officialTitle":151,"acronym":4,"eligibilityCriteria":152,"healthyVolunteers":11,"sex":17,"minAge":107,"maxAge":108,"enrollmentInfo":153,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":155,"conditions":156,"keywords":160,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":167,"lastUpdatePostDateStruct":168,"startDateStruct":170,"completionDateStruct":172,"leadSponsor":174,"locationsCount":44},"100539387","nidcd-otolaryngology-clinical-protocol-biospecimen-bank-100539387","NCT06303180","NIDCD Otolaryngology Clinical Protocol Biospecimen Bank","* INCLUSION CRITERIA\n\nIn order to be eligible to participate in this study, an individual must meet all of the following criteria:\n\n* Ability to provide their own consent, or for minors, a parent or guardian is able to consent on their behalf.\n* Ability of subject (or Legally Authorized Representative (LAR) to understand and the willingness to sign a written informed consent document.\n* Have a hearing, balance, smell, taste, voice, speech or language condition for which the subject is under clinical care or research purposes under a separate Review Board (IRB) approved protocol; OR be a healthy volunteer aged at least 3 years, enrolled on an approved research protocol.\n\nEXCLUSION CRITERIA\n\nAn individual who meets any of the following criteria will be excluded from participation in this study:\n\n* Have active symptomatic major organ disorders that would increase the risk of biopsy for research, including but not limited to bleeding disorders, ischemic heart disease, a recent myocardial infarction, active congestive heart failure or severe pulmonary dysfunction\n* Have specific medical condition, such as a bleeding tendency where additional biopsies or phlebotomy procedures may increase the subjects risk in participating. This will be determined at the discretion of the principal investigator.",{"count":154,"type":22},1000,"Background:\n\nMany disorders of the head and neck can affect a person s hearing; balance; smell; taste; swallowing; voice; or speech. These disorders include cancers and genetic and inflammatory diseases. To find better ways to diagnose and treat these disorders, researchers need to study tissues and other biological samples from people who have them.\n\nObjective:\n\nTo collect biological samples for a repository that will be used for research.\n\nEligibility:\n\nPeople of any age with a disorder of the head and neck that requires the taking of biological samples. The conditions may be any that affect hearing; balance; smell; taste; swallowing; voice; or speech.\n\nDesign:\n\nPart 1: Participants will give permission for their leftover tissue samples to be used for research. These are tissue samples from the head and neck that were collected in the course of routine tests and care or other research studies. Information on each participant s age, diagnosis, and previous treatments will also be collected.\n\nPart 2: Some participants may be asked for more samples. All those aged 3 years or older will have a physical exam. They will provide blood and saliva samples. A cotton swab or brush will be used to collect cells from the inside of the cheek.\n\nParticipants 18 years or older may have additional tests. They may provide nasal secretions: A piece of gelfoam or a sponge will be placed in the nose to soak up secretions for 5 to 10 minutes. They may have biopsies: Small samples of tissue will be cut from the skin and the tissue lining the mouth.\n\nSamples may be used for genetic testing.",[85,157,158,159],"Head and Neck Neoplasms","Hearing Disorders","Laryngeal Disease",[32,161,137,162,163,164,165,166],"Balance","Taste","SMELL","Tissue Sample","Genomic DNA","Saliva","2025-11-13",{"date":169,"type":38},"2025-11-14",{"date":171,"type":38},"2024-03-04",{"date":173,"type":22},"2033-12-30",{"name":42,"class":43},""]